Ein australischer Wert, der diverse Spitzenmedikamente in der Pipeline hat. U.a. hat vor kurzem ein Leukämie- und Brustkrebsmedikament erfolgreich die Phase I absolviert. Hier die dazugehörige Meldung. Weiter unten poste ich dann die letzten Quartalszahlen.
Anti-Cancer Drug Successfully Completes Phase 1 Human Trial
Announced on 2000/06/28 12:11:16.
Adelaide-based biotechnology company BresaGen Limited today announced
successful completion of the Phase 1 human safety trial for its
revolutionary anti-cancer drug E21R. The trial was conducted at the
Royal Adelaide Hospital Cancer Centre.
E21R, a potential therapeutic drug for the treatment of various
cancers - such as leukemia and breast cancer - was found to be safe
and well-tolerated at all doses tested.
BresaGen will now seek approval for Phase II clinical trials, to test
the therapeutic effectiveness of E21R, initially in myeloid leukemia
patients who are most likely to benefit from the drug. The first
Phase II trial is expected to begin in September 2000 at several
clinical centres around Australia. Funding for the Phase II trials
will be assisted by BresaGen's 1998 AusIndustry START Grant of $2.9
million.
In the recently completed Phase I safety trial, 19 patients received
a daily injection of E21R for 10 days, and were then monitored for a
further 18 days.
Professor Ian Olver, Clinical Director of the Royal Adelaide Hospital
Cancer Centre, and Principal Investigator for the trial, said: "We
have established the safety of the drug in humans at the full range
of doses tested."
"Phase I trials are a key step in the overall drug development
process because it is the first time a drug is tested in humans,"
said BresaGen's Managing Director, Dr John Smeaton. "Naturally, we
are very excited about the results."
"The Phase I trial also enabled us to collect data about the
stability and half-life of E21R in humans. E21R is well on its way
through clinical development."
E21R is an important component of BresaGen's product development
portfolio and compliments the exciting Cell Therapy program. The
company has a good mix of products at various stages of research,
development, clinical trials and sales.
For more information contact:
Dr Meera Verma, General Manager Prof Ian Olver, Clinical Director
Protein Pharmaceutical Division Royal Adelaide Hospital Cancer
BresaGen Limited Centre
Tel +61 8 8234 2660 Tel +61 8 8222 5577
email: mverma@bresagen.com.au
Website:
www.bresagen.com.au--------------------------------------------------
Und hier die letzten Quartalszahlen:
EN LIMITED 2000-07-27 ASX-SIGNAL-G
HOMEX - Adelaide
+++++++++++++++++++++++++
APPENDIX 4C
QUARTERLY REPORT FOR ENTITIES
ON BASIS OF COMMITMENTS
Name of entity
Bresagen Limited
ACN or ARBN Quarter ended ("current quarter")
007 988 767 30/06/2000
CONSOLIDATED STATEMENT OF CASH FLOWS
Cash flows related to Current Year to date
operating activities Quarter (12 months)
AUD'000 AUD'000
1.1 Receipts from customers 612 2,291
1.2 Payments for
(a) staff costs (712) (2,520)
(b) advertising & marketing (27) (109)
(c) research & development (1,182) (2,718)
(d) leased assets - -
(e) other working capital(1) 543 (731)
1.3 Dividends received - -
1.4 Interest and other items of
a similar nature received 230 587
1.5 Interest and other costs of
finance paid - -
1.6 Income taxes paid - -
1.7 Other (provide details if material) - -
1.8 Net Operating Cash Flows (536) (3,200)
(1) Due to a misallocation of amounts disclosed in previous quarters
under items 1.2(a) and (c) a one-off adjustment has been made to
correct the year-to date amount. The correct amount for the
current quarter is ($185)
Cash flows related to investing activities
1.9 Payment for acquisition of:
(a) businesses (item 5) - -
(b) equity investments - -
(c) intellectual property - -
(d) physical non-current assets (275) (385)
(e) other non-current assets - -
1.10 Proceeds from disposal of:
(a) businesses - -
(b) equity investments - -
(c) intellectual property - -
(d) physical non-current assets 18 18
(e) other non-current assets - -
1.11 Loans to other entities 2 (1)
1.12 Loans repaid by other entities - -
1.13 Other - Net payment for Commercial
Bills(2) - (3,908)
Net investing cash flows (255) (4,276)
1.14 Total operating and
investing cash flows (791) (7,476)
Cash flows related to financing activities
1.15 Proceeds from issues of
shares, options, etc. 10 18,873
1.16 Proceeds from sale of
forfeited shares - -
1.17 Proceeds from borrowings - -
1.18 Repayment of borrowings (8) (35)
1.19 Dividends paid - -
1.20 Other - Float & Placement costs incurred - (1,264)
Net financing cash flows 2 17,574
Net increase (decrease) in cash held (789) 10,098
1.21 Cash at beginning of quarter/
year to date(1) 12,005 1,118
1.22 Exchange rate adjustments to item 1.20 - -
1.23 Cash at end of quarter(2) 11,216 11,216
(1) Cash has been reclassified to include commercial bills with a
maturity date of less than 3 months from the end of the period.
(2) $4m has been invested in Bank Bills with a maturity date of
greater than 3 months from the end of the current quarter. This
amount is not shown as cash at the end of the quarter.
PAYMENTS TO DIRECTORS OF THE ENTITY AND ASSOCIATES OF THE DIRECTORS
PAYMENTS TO RELATED ENTITIES AND ASSOCIATES OF THE RELATED ENTITIES
Current Quarter
AUD'000
1.24 Aggregate amount of payments to
the parties included in item 1.2 32
1.25 Aggregate amount of loans to the
parties included in item 1.11 -
1.26 Explanation necessary for an understanding
of the transactions
-
NON-CASH FINANCING AND INVESTING ACTIVITIES
2.1 Details of financing and investing transactions which have had a
material effect on consolidated assets and liabilities but did
not involve cash flows
-
2.2 Details of outlays made by other entities to establish or
increase their share in businesses in which the reporting entity
has an interest
-
FINANCING FACILITIES AVAILABLE
Add notes as necessary for an understanding of the position.
Amount Amount
available used
AUD'000 AUD'000
3.1 Loan facilities - -
3.2 Credit standby arrangements 207 7
RECONCILIATION OF CASH
Reconciliation of cash at the end Current Previous
of the quarter (as shown in the quarter quarter
consolidated statement of cash flows) AUD'000 AUD'000
to the related items in the accounts
is as follows.
4.1 Cash on hand and at bank 1,000 1,136
4.2 Deposits at call - -
4.3 Bank overdraft - -
4.4 Other - represents Commercial Bills
maturing within 3 months of current
quarter end 10,216 10,869
Total: cash at end of quarter (item 1.22) 11,216 12,005
ACQUISITIONS AND DISPOSALS OF BUSINESS ENTITIES
Acquisitions Disposals
(item 1.9(a)) (Item 1.10(a))
5.1 Name of entity N/A N/A
5.2 Place of incorporation
or registration - -
5.3 Consideration for
acquisition or disposal - -
5.4 Total net assets - -
5.5 Nature of business - -
COMPLIANCE STATEMENT
1. This statement has been prepared under accounting policies which
comply with accounting standards as defined in the Corporations Law
or other standards acceptable to ASX.
2. This statement does give a true and fair view
of the matters disclosed.
L W P Burns
COMPANY SECRETARY Date: 27/07/2000
--------------------------------------------------
BresaGen hat am 11.8.00 mit 1,50 A$ geschlossen. Die WKN lautet
934790. Die Aktie ist nur über die australische Börse zu beziehen, den Auftrag leitet jede Bank weiter.
KAUFAUFTRÄGE SIND WEGEN DER GERINGEN VOLUMEN (ca. 30.000 bis 40000 Stück pro Tag) ZU LIMITIEREN !!!
Ich bin überzeugt, dass in absehbarer Zeit das letzte ATH (1,80 A$) nicht nur erreicht, sondern deutlich überschritten werden sollte, da weitere Medikamente kurz vor Abschluss der Testphase bzw. kurz vor der Zulassung stehen.
Fragen / Meinungen ?
Gruß
Fluffy
